AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15682366 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT cardiac quantification (GSCQ) method
Number of subjects: 0
Study 12131314 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.9 mg daily oxybutynin TDS
Number of subjects: 520
Study 12131314 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6 mg daily oxybutynin TDS
Number of subjects: 520
Study 12131314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 10102962 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (1 g sucralfate q.d.s. for 28 days, 300 mg metronidazole q.d.s. for 14 days, 250 mg clarithromycin q.d.s. for 14 days)
Number of subjects: 114
Study 10102962 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg q.d.s. for 12 months)
Number of subjects: 114
Study 10102962 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole group
Number of subjects: 114
Study 10102962 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy group
Number of subjects: 114
Study 10102962 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori negative patients
Number of subjects: 114
Study 10102962 — intervention group
Group type: COMPARATOR
Intervention: H. pylori positive patients
Number of subjects: 114
Study 10102962 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori negative patients after mean follow-up of 4.07 years
Number of subjects: 114
Study 10102962 — intervention group
Group type: COMPARATOR
Intervention: H. pylori positive patients after mean follow-up of 4.07 years
Number of subjects: 114
Study 8528688 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced services group (mandatory school and work requirements, financial sanctions, support services such as case management, parenting workshops, child care assistance, education and training opportunities)
Number of subjects: 0
Study 8528688 — intervention group
Group type: COMPARATOR
Intervention: Regular services group (control group)
Number of subjects: 0
Study 8528688 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced services group
Number of subjects: 0
Study 8528688 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced services group (most engaged in self-sufficiency activities)
Number of subjects: 0
Study 2262904 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (15, 30 and 45 mg)
Number of subjects: 15
Study 2262904 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5 and 0.75 mg)
Number of subjects: 15
Study 2262904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30324837 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day estradiol valerate plus 4 mg/day medroxyprogesterone acetate on days 19‐30 (Group A)
Number of subjects: 96
Study 30324837 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day estradiol valerate plus 100 mg/day micronized progesterone on days 19‐30 (Group B)
Number of subjects: 96
Study 30324837 — intervention group
Group type: COMPARATOR
Intervention: Cimicifuga foetida extract, 1 tablet (contains 33.3 mg extract), t.i.d. (Group C)
Number of subjects: 96
Study 30022759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod oral liquid
Number of subjects: 76
Study 30022759 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (ganciclovir for injection and symptomatic treatment)
Number of subjects: 76
Study 27030629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (IHE)
Number of subjects: 16
Study 27030629 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (C)
Number of subjects: 16
Study 25377429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 2.5 mg/kg/day
Number of subjects: 65
Study 25377429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 5 mg/kg/day
Number of subjects: 65
Study 25377429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 10 mg/kg/day
Number of subjects: 65
Study 25377429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 15 mg/kg/day
Number of subjects: 65
Study 25377429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 25377429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 65
Study 25377429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (up to 10 mg/kg/day for ages 1 month to 16 years; up to 15 mg/kg/day for ages <6 years)
Number of subjects: 65
Study 22202713 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary thermodilution
Number of subjects: 120
Study 22202713 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter
Number of subjects: 120
Study 21512813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg intravenously before tourniquet inflation and 3 hours postoperatively; 250 mg orally, two capsules three times daily for 5 days)
Number of subjects: 100
Study 21512813 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 21512813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100
Study 17284888 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐h sleep restriction (from 0100 to 0600) for 7 d
Number of subjects: 13
Study 17284888 — intervention group
Group type: COMPARATOR
Intervention: 8‐h sleep (from 2300 to 0700) for 7 d
Number of subjects: 13
Study 16060124 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (29 mg, range 0-160 mg) every 6 h
Number of subjects: 29
Study 16060124 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (60 mg, range 0-240 mg) every 6 h
Number of subjects: 29
Study 16060124 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide and Furosemide (both groups)
Number of subjects: 29
Study 16060124 — intervention group
Group type: COMPARATOR
Intervention: Furosemide group
Number of subjects: 29
Study 16060124 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide group
Number of subjects: 29
Study 12017410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/d
Number of subjects: 423
Study 12017410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 10399974 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine (short-acting anesthetic)
Number of subjects: 99
Study 10399974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (long-acting anesthetic)
Number of subjects: 99
Study 10399974 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 99
Study 7752872 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-only (S) group
Number of subjects: 30
Study 7752872 — intervention group
Group type: COMPARATOR
Intervention: Endurance-only (E) group
Number of subjects: 30
Study 7752872 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (C) group
Number of subjects: 30
Study 2277569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose epidural morphine (2 mg) and 75 mg diclofenac sodium i.m. postoperatively (Group B)
Number of subjects: 50
Study 2277569 — intervention group
Group type: COMPARATOR
Intervention: Low dose epidural morphine (2 mg) and 3 ml normal saline i.m. at recovery room (Group A)
Number of subjects: 50
Study 316976 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic propranolol treatment postoperatively
Number of subjects: 42
Study 316976 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (nontreatment group)
Number of subjects: 42
Study 316976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of intravenous propranolol therapy
Number of subjects: 42
Study 31587479 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular and histopathological study using PCR assays and histopathology on ocular tissues
Number of subjects: 100
Study 31160473 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Patient (SP) method
Number of subjects: 87
Study 31160473 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based education method (Control)
Number of subjects: 87
Study 29016626 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI)
Number of subjects: 27
Study 29016626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29016626 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of PPI
Number of subjects: 27
Study 29016626 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of PPI
Number of subjects: 27
Study 26693446 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtuse curved shaft needles
Number of subjects: 45
Study 26693446 — intervention group
Group type: EXPERIMENTAL
Intervention: Arch-shape shaft needles
Number of subjects: 45
Study 26693446 — intervention group
Group type: COMPARATOR
Intervention: Straight shaft needles
Number of subjects: 45
Study 22866876 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ROADMAP intervention group
Number of subjects: 0
Study 22866876 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 22023278 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive interpretation bias modification
Number of subjects: 67
Study 22023278 — intervention group
Group type: COMPARATOR
Intervention: Negative interpretation bias modification
Number of subjects: 67
Study 22023278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias modification (both positive and negative)
Number of subjects: 67
Study 19810125 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 0
Study 19810125 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemoradiotherapy (CCRT)
Number of subjects: 0
Study 19810125 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) and hyperfractionation (HF)
Number of subjects: 0
Study 19810125 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 0
Study 17309587 — intervention group
Group type: EXPERIMENTAL
Intervention: New brush heads
Number of subjects: 34
Study 17309587 — intervention group
Group type: COMPARATOR
Intervention: 3-month-old worn brush heads
Number of subjects: 34
Study 15521106 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (800 mg/day)
Number of subjects: 150
Study 15521106 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC; 1 mg/kg.day)
Number of subjects: 150
Study 15521106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of penicillin and DEC (at the same doses)
Number of subjects: 150
Study 15521106 — intervention group
Group type: EXPERIMENTAL
Intervention: Framycetin ointment
Number of subjects: 150
Study 15521106 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets and placebo ointment
Number of subjects: 150
Study 11437861 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes specialist nursing (DSN) service
Number of subjects: 0
Study 11437861 — intervention group
Group type: COMPARATOR
Intervention: Standard in‐patient care (Control)
Number of subjects: 0
Study 9684133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin infusion (Omnibionta) including 10 mg of alpha‐tocopherol acetate, 2 mg of DL‐alpha‐tocopherol, and 1 g of ascorbate
Number of subjects: 58
Study 9684133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin infusion (Omnibionta)
Number of subjects: 58
Study 9684133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant treatment)
Number of subjects: 58
Study 8113062 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH program implementation
Number of subjects: 0
Study 8113062 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH process evaluation system
Number of subjects: 0
Study 8113062 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH process measures and data collection protocols
Number of subjects: 0
Study 3072356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 160
Study 3072356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 300 mg
Number of subjects: 160
Study 3072356 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg plus Codeine 60 mg
Number of subjects: 160
Study 3072356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 30820571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweets with warnings
Number of subjects: 994
Study 30820571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweets featuring e‐cigarette products
Number of subjects: 994
Study 30820571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweets featuring e‐cigarette use
Number of subjects: 994
Study 30820571 — intervention group
Group type: COMPARATOR
Intervention: Tweets without warnings
Number of subjects: 994
Study 30820571 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings
Number of subjects: 994
Study 30265306 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg progesterone vaginal pessaries bid
Number of subjects: 147
Study 30265306 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg progesterone vaginal pessaries bid
Number of subjects: 147
Study 30265306 — intervention group
Group type: COMPARATOR
Intervention: 90 mg progesterone vaginal gel od
Number of subjects: 147
Study 30265306 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg progesterone vaginal pessaries bid
Number of subjects: 147
Study 30265306 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg progesterone vaginal pessaries od
Number of subjects: 147
Study 30265306 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal pessaries bid
Number of subjects: 147
Study 28699555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Clusters (IC)
Number of subjects: 11933
Study 28699555 — intervention group
Group type: COMPARATOR
Intervention: Control Clusters (CC)
Number of subjects: 11933
Study 25769395 — intervention group
Group type: EXPERIMENTAL
Intervention: SG1 (Urethral catheter removal at 48 hours post-operatively)
Number of subjects: 44
Study 25769395 — intervention group
Group type: COMPARATOR
Intervention: SG2 (Urethral catheter removed following cessation of epidural analgesia)
Number of subjects: 44
Study 25769395 — intervention group
Group type: EXPERIMENTAL
Intervention: SG1
Number of subjects: 44
Study 25769395 — intervention group
Group type: COMPARATOR
Intervention: SG2
Number of subjects: 44
Study 23552821 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET, n = 15)
Number of subjects: 39
Study 23552821 — intervention group
Group type: COMPARATOR
Intervention: Health Education without Training (EA, n = 14)
Number of subjects: 39
Study 21199812 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 229
Study 21199812 — intervention group
Group type: EXPERIMENTAL
Intervention: MI with feedback (MIFB)
Number of subjects: 229
Study 21199812 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback (FB)
Number of subjects: 229
Study 21199812 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment only (AO)
Number of subjects: 229
Study 18040702 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stabilization within 8 hours of spinal cord injury (Group I, n=12)
Number of subjects: 27
Study 18040702 — intervention group
Group type: COMPARATOR
Intervention: Surgical stabilization between 3 and 15 days after injury (Group II, n=15)
Number of subjects: 27
Study 16464703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy for Adolescents (CBGT‐A)
Number of subjects: 23
Study 16464703 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Adolescents‐‐Spanish version (SET‐Asv)
Number of subjects: 23
Study 16464703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervención en Adolescentes con Fobia Social‐‐Treatment for Adolescents with Social Phobia (IAFS)
Number of subjects: 23
Study 14742328 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 33
Study 14742328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 33
Study 14742328 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with bupivacaine
Number of subjects: 33
Study 11704914 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-EOB-DTPA (3, 6, 12.5, 25, and 50 micromol/kg b. w. as a bolus injection)
Number of subjects: 61
Study 11704914 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA (0.1 mmol/kg b. w. as a bolus injection)
Number of subjects: 61
Study 9390615 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (IH group)
Number of subjects: 20
Study 9390615 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (IV group)
Number of subjects: 20
Study 9390615 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 8184127 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill training
Number of subjects: 63
Study 8184127 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional stimulation approach
Number of subjects: 63
Study 8184127 — intervention group
Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 63
Study 3579008 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 11% O2
Number of subjects: 15
Study 3579008 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100% O2
Number of subjects: 15
Study 3579008 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cutaneous spider nevi
Number of subjects: 15
Study 3579008 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 15
Study 29346040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab maintenance
Number of subjects: 491
Study 29346040 — intervention group
Group type: COMPARATOR
Intervention: No treatment (observation)
Number of subjects: 491
Study 29346040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab maintenance (per-protocol population)
Number of subjects: 491
Study 29346040 — intervention group
Group type: COMPARATOR
Intervention: No treatment (observation) (per-protocol population)
Number of subjects: 491
Study 27720942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematoporphyrin PDT and stent placement (PDT+stent group)
Number of subjects: 39
Study 27720942 — intervention group
Group type: COMPARATOR
Intervention: Stent-only (stent group)
Number of subjects: 39
Study 25033137 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered HIV information
Number of subjects: 112
Study 25033137 — intervention group
Group type: COMPARATOR
Intervention: General health information
Number of subjects: 112
Study 23553347 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrive with Me (TWM) intervention
Number of subjects: 124
Study 20502739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphurous thermal water inhalations
Number of subjects: 80
Study 20502739 — intervention group
Group type: COMPARATOR
Intervention: Physiological solution
Number of subjects: 80
Study 18939349 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiburst mode
Number of subjects: 101
Study 18939349 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortpulse mode
Number of subjects: 101
Study 18939349 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitestar technology
Number of subjects: 101
Study 16364549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fake analgesic cream)
Number of subjects: 19
Study 16364549 — intervention group
Group type: COMPARATOR
Intervention: No placebo condition
Number of subjects: 19
Study 14505118 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral graded activity (BGA) program
Number of subjects: 105
Study 14505118 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 105
Study 11707882 — intervention group
Group type: EXPERIMENTAL
Intervention: Toddler-parent psychotherapy (TPP)
Number of subjects: 63
Study 11707882 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 63
Study 11707882 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed control group
Number of subjects: 63
Study 8680609 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance assessed using the frequently sampled intravenous glucose tolerance test with minimal model analysis
Number of subjects: 1600
Study 8680609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimal-medial carotid artery wall thickness measured using B-mode ultrasonography
Number of subjects: 1600
Study 8680609 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent CVD assessed by questionnaire and resting electrocardiography
Number of subjects: 1600
Study 2615196 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronicity Index (CI)
Number of subjects: 84
Study 2615196 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Index (AI)
Number of subjects: 84
Study 795261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (S 35)
Number of subjects: 125
Study 795261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (F 38)
Number of subjects: 125
Study 795261 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (X 52)
Number of subjects: 125
Study 31811378 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D visualisations
Number of subjects: 91
Study 31811378 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed model
Number of subjects: 91
Study 31811378 — intervention group
Group type: COMPARATOR
Intervention: Photographs
Number of subjects: 91
Study 30604599 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, Sitagliptin, and Acarbose (Met+Sita+Acarb)
Number of subjects: 165
Study 30604599 — intervention group
Group type: COMPARATOR
Intervention: Metformin and Sitagliptin (Met+Sita)
Number of subjects: 165
Study 28712940 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 140
Study 28712940 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 140
Study 25311708 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformational positioner
Number of subjects: 25
Study 25311708 — intervention group
Group type: COMPARATOR
Intervention: Standard mattress
Number of subjects: 25
Study 25311708 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical subjects
Number of subjects: 25
Study 23386424 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normobaric hypoxia at rest (PHE)
Number of subjects: 20
Study 23386424 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normobaric hypoxia during exercise (AHE)
Number of subjects: 20
Study 23386424 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 20